Clinical Research Directory
Browse clinical research sites, groups, and studies.
Safety, Tolerability, and Pharmacokinetics of Lumateperone Long-Acting Injectable Formulations in Patients With Schizophrenia or Schizoaffective Disorder
Sponsor: Intra-Cellular Therapies, Inc.
Summary
Study ITI-007-037 is a Phase 1b, open-label study to evaluate the safety, tolerability, and PK of lumateperone long-acting injectable (LAI) formulations after a single intramuscular injection in patients with stale schizophrenia or schizoaffective disorder.
Official title: A Phase 1b, Open-label Study to Determine the Pharmacokinetics, Safety, and Tolerability of Single, Ascending Doses of Lumateperone Long-acting Injectable Formulations Administered Intramuscularly to Patients With Schizophrenia or Schizoaffective Disorder
Key Details
Gender
All
Age Range
18 Years - 55 Years
Study Type
INTERVENTIONAL
Enrollment
52
Start Date
2024-08-23
Completion Date
2025-11-20
Last Updated
2026-07-31
Healthy Volunteers
No
Conditions
Interventions
Lumateperone Capsule
Lumateperone 42 mg capsule, oral administration
Lumateperone LAI
Lumateperone LAI X500-E2 IM injection
Lumateperone LAI
Lumateperone LAI X500-E3 IM injection
Lumateperone LAI
Lumateperone LAI X500-X2 IM injection
Lumateperone LAI
Lumateperone LAI X500-X5 IM injection
Lumateperone LAI
Lumateperone LAI (X500-E2 or X500-E3 or X500-X2 or X500-X5) IM injection
Locations (4)
Collaborative Neuroscience Research, LLC
Los Alamitos, California, United States
CenExeli Research LLC
Atlanta, Georgia, United States
Atlanta Center for Medical Research
Atlanta, Georgia, United States
Hassman Research Institute, LLC.
Marlton, New Jersey, United States